Tvardi Therapeutics (NASDAQ:TVRD) Cut to Sell at Wall Street Zen

Tvardi Therapeutics (NASDAQ:TVRD) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Other equities research analysts have also issued reports about the company. Lucid Cap Mkts upgraded Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 4th. Weiss Ratings reiterated a “sell (e)” rating on shares of Tvardi Therapeutics in a report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $55.50.

Tvardi Therapeutics Stock Down 1.5%

TVRD stock opened at $3.99 on Friday. The company has a market cap of $37.43 million, a price-to-earnings ratio of -0.41 and a beta of 0.14. The business has a fifty day simple moving average of $4.08 and a 200-day simple moving average of $13.10. Tvardi Therapeutics has a 52 week low of $3.50 and a 52 week high of $43.65.

Institutional Investors Weigh In On Tvardi Therapeutics

Several hedge funds have recently modified their holdings of TVRD. JPMorgan Chase & Co. purchased a new position in Tvardi Therapeutics in the 2nd quarter worth approximately $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Tvardi Therapeutics during the second quarter worth $43,000. Headlands Technologies LLC acquired a new position in shares of Tvardi Therapeutics during the second quarter worth $80,000. New York State Common Retirement Fund purchased a new position in shares of Tvardi Therapeutics in the second quarter valued at $92,000. Finally, Squarepoint Ops LLC acquired a new stake in Tvardi Therapeutics during the 3rd quarter valued at $318,000. 44.66% of the stock is currently owned by hedge funds and other institutional investors.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.